Business Context and Reporting Period
This Form 8-K is a current report filed by ScoutCam Inc. (not Odysight.Ai Inc.) on May 19, 2020. The registrant is incorporated in Nevada and is based in Omer, Israel. The filing reports on events occurring on May 18, 2020, specifically the closing of a private placement of equity securities and related corporate governance changes.
Key Financial Metrics and Transaction Details
The filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Aggregate Proceeds: US$2,000,000.
- Securities Issued: 2,066,116 Units sold to M. Arkin (1999) Ltd.
- Purchase Price: US$0.968 per Unit.
- Unit Composition: Each Unit consists of two shares of Common Stock, one Warrant A (exercise price US$0.595), and two Warrant B (exercise price US$0.893).
- Total Shares Issued: 4,132,232 shares of Common Stock.
- Total Warrants Issued: 2,066,116 Warrant A and 4,132,232 Warrant B.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Corporate Actions
Material changes reported in this filing include:
- Unregistered Sale of Equity: The Company consummated a securities purchase agreement under Regulation S, resulting in significant dilution through the issuance of shares and warrants.
- Board Appointment: Ms. Irit Yaniv, a designee of the investor (Arkin), was appointed to the Board of Directors as a condition of the transaction.
- Voting Agreement: A voting agreement was executed between the Company, Arkin, and Medigus Ltd. (a controlling stockholder). This agreement requires Arkin and Medigus to vote in favor of each other's designated board representatives, contingent on maintaining specific beneficial ownership thresholds.
Outlook, Risks, and Contingencies
Registration Rights: The Company has undertaken to file a registration statement on Form S-1 within 90 days of the closing date to cover the resale of the issued securities.
Management Commentary: The filing highlights the appointment of Dr. Irit Yaniv, noting her extensive experience in the Medtech industry and her background in metabolic disorders, suggesting a strategic alignment with the Company's sector.
Risks: The filing does not explicitly list new risk factors, though the issuance of warrants with exercise prices below the purchase price (US$0.595 and US$0.893 vs. US$0.968) implies potential future dilution if exercised.
Investor Verification Checklist
- Verify the exact number of outstanding shares post-transaction to assess dilution impact.
- Confirm the terms of the Voting Agreement to understand the balance of power between Arkin and Medigus Ltd.
- Monitor the filing of the Form S-1 registration statement within the 90-day window.
- Review the press release (Exhibit 99.1) for additional context on the use of proceeds.
- Clarify the relationship between ScoutCam Inc. and Odysight.Ai Inc., as the filing name differs from the requested metadata.